journal
MENU ▼
Read by QxMD icon Read
search

Clinical Colorectal Cancer

journal
https://www.readbyqxmd.com/read/28712945/intestinal-and-extraintestinal-cancers-associated-with-inflammatory-bowel-disease
#1
REVIEW
Minna Chang, Liisa Chang, Hanna M Chang, Fuju Chang
Inflammatory bowel disease (IBD) with its 2 most common entities, ulcerative colitis and Crohn's disease, causes an increased risk of developing intestinal cancers. In fact, malignancies are the second most common cause of death after cardiovascular diseases in both sexes of patients with IBD. Risk factors for colorectal cancer in IBD correlate with the duration of the disease, extent of disease, the association with primary sclerosing cholangitis, family history, and early age at onset. Patients with IBD also have an increased risk for developing a variety of extraintestinal malignancies...
June 27, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28709877/impact-of-duration-of-neoadjuvant-radiation-on-rectal-cancer-survival-a-real-world-multi-center-retrospective-cohort-study
#2
Omar Abdel-Rahman, Aalok Kumar, Hagen F Kennecke, Caroline H Speers, Winson Y Cheung
BACKGROUND: The utility of neoadjuvant radiotherapy (nRT) for the treatment of stage II and III rectal cancer is well-established. However, the optimal duration of nRT in this setting remains controversial. Using a population-based cohort of patients with stage II and III rectal cancer (RC) treated with curative intent, our aims were to (1) examine the patterns of nRT use and (2) explore the relationship between different nRT schedules and survival in the real-world setting. METHODS: This is a multi-center retrospective cohort study based on population-based data from 5 regional comprehensive cancer centers in British Columbia, Canada...
June 23, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28709876/is-cure-possible-after-sequential-resection-of-hepatic-and-pulmonary-metastases-from-colorectal-cancer
#3
Muthukumarassamy Rajakannu, Pierre Magdeleinat, Eric Vibert, Oriana Ciacio, Gabriella Pittau, Pasquale Innominato, Antonio SaCunha, Daniel Cherqui, Jean-François Morère, Denis Castaing, René Adam
BACKGROUND: Surgical resection is an established therapeutic strategy for colorectal cancer (CRC) metastasis. However, controversies exist when CRC liver and lung metastases (CLLMs) are found concomitantly or when recurrence develops after either liver or lung resection. No predictive score model is available to risk stratify these patients in preparation for surgery, and cure has not yet been reported. PATIENTS AND METHODS: All consecutive patients who had undergone surgery for CLLMs at our institution during a 20-year period were reviewed...
June 23, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28669606/dose-response-effects-of-aerobic-exercise-among-colon-cancer-survivors-a-randomized-phase-ii-trial
#4
Justin C Brown, Andrea B Troxel, Bonnie Ky, Nevena Damjanov, Babette S Zemel, Michael R Rickels, Andrew D Rhim, Anil K Rustgi, Kerry S Courneya, Kathryn H Schmitz
BACKGROUND: Observational studies suggest that higher volumes of physical activity are associated with a lower risk of disease recurrence among survivors of colon cancer. However, the feasibility and safety of prescribing higher volumes of physical activity to survivors of colon cancer are unknown. Furthermore, the pathways through which exercise may reduce disease recurrence are unknown. PATIENTS AND METHODS: Survivors of stage I to III colon cancer were randomized to usual-care control, 150 minutes per week of aerobic exercise (low-dose), or 300 minutes per week of aerobic exercise (high-dose)...
June 17, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28365393/peripheral-neutrophil-to-lymphocyte-ratio-improves-prognostication-in-colon-cancer
#5
Shahrooz Rashtak, Xiaoyang Ruan, Brooke R Druliner, Hongfang Liu, Terry Therneau, Mohamad Mouchli, Lisa A Boardman
BACKGROUND: We studied the role of peripheral neutrophil to lymphocyte ratio (NLR) on survival outcomes in colon and rectal cancer to determine if its inclusion improved prognostication within existing staging systems. PATIENTS AND METHODS: Disease-free (DFS) and overall survival (OS) hazard ratios (HRs) of pretreatment NLR were calculated for 2536 patients with stage I to III colon or rectal cancer and adjusted for age, positive/total number of nodes, T stage, and grade...
June 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/27670891/exploring-the-prognostic-role-of-microsatellite-instability-in-patients-with-stage-ii-colorectal-cancer-a-systematic-review-and-meta-analysis
#6
Adriana Romiti, Eliana Rulli, Emanuela Pilozzi, Chiara Gerardi, Michela Roberto, Lorenzo Legramandi, Rosa Falcone, Ilaria Pacchetti, Paolo Marchetti, Irene Floriani
BACKGROUND: Many studies have disclosed the prognostic effect of microsatellite instability (MSI) and/or loss of mismatch repair proteins in colorectal cancer. Nevertheless, little evidence supports their role in the decision-making of adjuvant therapy for patients with stage II disease. MATERIALS AND METHODS: The aim of this systematic review was to evaluate the prognostic and/or predictive role of MSI status in patients with stage II colorectal cancer on disease-free survival and overall survival...
June 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28527628/multidisciplinary-clinics-for-colorectal-cancer-care-reduces-treatment-time
#7
Vanessa N Kozak, Alok A Khorana, Sudha Amarnath, Katherine E Glass, Matthew F Kalady
INTRODUCTION: Management of locally advanced and metastatic colorectal cancer (CRC) requires the expertise of multiple specialists. Multidisciplinary clinics (MDCs) are a working model designed to facilitate delivery of coordinated care. The present study evaluated the effects of MDC on the time to treatment (TTT). PATIENTS AND METHODS: Patients with CRC or locally advanced anal cancer who were evaluated at a single-institution MDC from January 2014 to October 2015 were identified from an institutional registry...
April 19, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28465170/treatment-of-patients-with-metastatic-colorectal-cancer-in-a-real-world-scenario-probability-of-receiving-second-and-further-lines-of-therapy-and-description-of-clinical-benefit
#8
Marco Tampellini, Massimo Di Maio, Chiara Baratelli, Lorenzo Anania, Maria Pia Brizzi, Cristina Sonetto, Anna La Salvia, Giorgio Vittorio Scagliotti
BACKGROUND: The optimal therapeutic strategy for metastatic colorectal cancer patients is still a matter of debate. There are no prognostic variables indicating how many lines individual patients ought to receive, and whether later lines could be effective even when earlier ones were not. PATIENTS AND METHODS: We retrospectively collected data from 420 consecutive patients with metastatic colorectal cancer at our institution, describing the proportion of patients who received second or later lines of therapy and the chance of a line of treatment being active when the previous line was not...
April 8, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28687458/effectiveness-of-screening-modalities-in-colorectal-cancer-a-network-meta-analysis
#9
REVIEW
Jianping Zhang, Zhiyuan Cheng, Yubao Ma, Caili He, Yongbin Lu, Yaxue Zhao, Xiaoyu Chang, Yawei Zhang, Yana Bai, Ning Cheng
The aim of the study was to evaluate on the effectiveness of screening modalities in the prevention of colorectal cancer (CRC) occurrence and deaths. General meta-analysis was performed to produce pooled estimates of the effect of CRC incidence and mortality using a search of PubMed, Web of Science, and the Cochrane Library for eligible studies from January 1992 to March 2016. A network meta-analysis was performed to synthetically compare the effectiveness of 5 frequently used screening modalities. A total of 44 studies with a focus on mortality from CRC using different screening methods were included...
April 4, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28454726/predictive-value-of-early-tumor-shrinkage-and-density-reduction-of-lung-metastases-in-patients-with-metastatic-colorectal-cancer-treated-with-regorafenib
#10
Hannes Vanwynsberghe, Xander Verbeke, Johan Coolen, Eric Van Cutsem
INTRODUCTION: The benefit of regorafenib in colorectal cancer is not very pronounced. At present, there is lack of predictive biological or radiological markers. We studied if density reduction or small changes in size of lung metastases could be a predictive marker. METHODS: We retrospectively measured density in size of lung metastases of all patients included in the CORRECT and CONSIGN trials at our center. Contrast-enhanced CT scan at baseline and at week 8 were compared...
March 29, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28433601/volumetric-versus-unidimensional-measures-of-metastatic-colorectal-cancer-in-assessing-disease-response
#11
Meghan G Lubner, Nicholas Stabo, Sam J Lubner, Alejandro Munoz Del Rio, Chihwa Song, Perry J Pickhardt
INTRODUCTION: The purpose of this study was to compare unidimensional (1D/linear) and volumetric (3D) measures of metastatic colorectal cancer (mCRC) at computed tomography (CT) for predicting clinical outcome. PATIENTS AND METHODS: Analysis of CT images in 105 patients (mean age, 59 years; range, 25-81 years; 45 women, 60 men) receiving treatment for mCRC was performed. Both unidimensional and volumetric measures were obtained on index lesions at 3 time points (baseline/midpoint/post-therapy; mean interval, 4...
March 27, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28619608/real-world-direct-health-care-costs-for-metastatic-colorectal-cancer-patients-treated-with-cetuximab-or-bevacizumab-containing-regimens-in-first-line-or-first-line-through-second-line-therapy
#12
Stephen Johnston, Kathleen Wilson, Helen Varker, Elisabetta Malangone-Monaco, Paul Juneau, Ellen Riehle, Sacha Satram-Hoang, Nicolas Sommer, Sarika Ogale
BACKGROUND: The present study examined real-world direct health care costs for metastatic colorectal cancer (mCRC) patients initiating first-line (1L) bevacizumab (BEV)- or cetuximab (CET)-containing regimen in 1L or 1L-through-second-line (1L-2L) therapy. PATIENTS AND METHODS: Using a large US insurance claims database, patients with mCRC initiating 1L BEV- or 1L CET-containing regimen from January 1, 2008 to September 30, 2014 were identified. The per-patient per-month (PPPM) all-cause health care costs (2014 US dollars) were measured during 1L therapy and, for patients continuing to a 2L biologic-containing regimen, 1L-2L therapy...
March 24, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28456481/significance-of-anemia-in-outcomes-after-neoadjuvant-chemoradiotherapy-for-locally-advanced-rectal-cancer
#13
John M McGrane, David J Humes, Austin G Acheson, Fiona Minear, James M D Wheeler, Catherine J Walter
BACKGROUND: Approximately one quarter of patients receiving neoadjuvant chemoradiotherapy (NCRT) for locally advanced rectal cancer will be anemic at presentation. The outcomes of these anemic patients have historically been less favorable. We assessed the potential of anemia to act as an independent biomarker for a poor prognosis in patients with locally advanced rectal cancer. MATERIALS AND METHODS: We performed a retrospective, observational study of consecutive patients with locally advanced rectal adenocarcinoma who underwent NCRT from 2004 to 2009 at 3 English National Health Service trusts...
March 24, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28434884/neurotoxicity-outcomes-in-a-population-based-cohort-of-elderly-patients-treated-with-adjuvant-oxaliplatin-for-colorectal-cancer
#14
Michael J Raphael, Hadas D Fischer, Kinwah Fung, Peter C Austin, Geoffrey M Anderson, Christopher M Booth, Simron Singh
BACKGROUND: The addition of oxaliplatin to adjuvant treatment regimens for colorectal cancer has been shown to improve overall survival at the expense of increased toxicity. The incidence and severity of toxicity might be greater among older patients who might also derive less benefit from oxaliplatin. We evaluated the association between adjuvant oxaliplatin-based chemotherapy and neurotoxicity outcomes in an elderly cohort of patients. PATIENTS AND METHODS: A population-based cohort of patients aged > 65 years with stage II and III colorectal cancer treated with adjuvant therapy in Ontario, Canada was identified using the Ontario Cancer Registry...
March 24, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28433602/folfoxiri-regimen-for-metastatic-colorectal-cancer-a-systematic-review-and-meta-analysis
#15
Frederico Leal, Fernanda Proa Ferreira, Andre Deeke Sasse
INTRODUCTION: Cytotoxic chemotherapy is the mainstay treatment for metastatic colorectal cancer (mCRC). Fluoropyrimidines, oxaliplatin, and irinotecan are the most active drugs; however, their optimal sequencing has not yet been established. Some evidence has shown that upfront treatment with 5-fluorouracil, oxaliplatin, and irinotecan (FOLFOXIRI regimen) can improve outcomes for patients with mCRC. MATERIALS AND METHODS: We performed a systematic search in electronic databases...
March 24, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28412137/are-markers-of-systemic-inflammation-good-prognostic-indicators-in-colorectal-cancer
#16
REVIEW
Sabrina Rossi, Michele Basso, Antonia Strippoli, Giovanni Schinzari, Ettore D'Argento, Mario Larocca, Alessandra Cassano, Carlo Barone
Systemic inflammation has been proved to play a crucial role in promoting cancer progression and metastasis in many cancer types, including colorectal cancer (CRC). The aim of the present review was to provide an overview of studies regarding the prognostic value of inflammation-based markers in patients with CRC. A literature search was performed for articles reporting the prognostic value of the Glasgow prognostic score (GPS), modified GPS (mGPS), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) in relation to CRC outcomes...
March 24, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28410832/a-dose-finding-and-biomarker-evaluation-phase-ib-study-of-everolimus-in-association-with-5-fluorouracil-and-pelvic-radiotherapy-as-neoadjuvant-treatment-of-locally-advanced-rectal-cancer-e-larc-study
#17
Fabio Gelsomino, Federica Bertolini, Gabriele Luppi, Andrea Spallanzani, Elisa Pettorelli, Luca Reggiani Bonetti, Bruno Meduri, Gianrocco Manco, Pierfranco Conte, Stefano Cascinu
BACKGROUND: During the past 20 years, considerable improvement has occurred in the treatment of patients with locally advanced rectal cancer (LARC). With the introduction of multimodal treatment, refinements in preclinical staging and improvements in surgical skills, local relapse is no longer the major problem for patients with LARC. However, many patients die of metastatic disease. The present phase Ib study aimed to establish the maximum tolerated dose of everolimus combined with 5-fluorouracil and radiotherapy in patients with LARC...
March 24, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28462853/comparing-clinical-characteristics-and-outcomes-of-young-onset-and-late-onset-colorectal-cancer-an-international-collaborative-study
#18
Young Soo Rho, Marine Gilabert, Karol Polom, Archil Aladashvili, Katerina Kopeckova, Vera Megdanova, Niamh Coleman, Megan Greally, Daniele Marrelli, Franco Roviello, Ray McDermott, Veneta Petrova, Zhasmina Mihaylova, Zbynek Bortlicek, Jana Prausova, Gerald Batist, Laurent Azoulay, Petr Kavan
BACKGROUND: Compared with the general population, the incidence of young-onset (YO) colorectal cancer (CRC) is increasing. However, a significant knowledge gap exists in the clinical characteristics, treatment patterns, and outcomes for these patients. MATERIALS AND METHODS: Six international tertiary cancer centers conducted a retrospective study. Patients with YO CRC (aged 18-44 years) and LO CRC (aged > 44 years) diagnosed with histologically proven colorectal adenocarcinoma from June 2003 to June 2014 were enrolled...
March 21, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28462852/stereotactic-robotic-body-radiotherapy-for-patients-with-unresectable-hepatic-oligorecurrence
#19
Patrick Berkovic, Akos Gulyban, Paul Viet Nguyen, David Dechambre, Philippe Martinive, Nicolas Jansen, Ferenc Lakosi, Levente Janvary, Philippe A Coucke
BACKGROUND: The purpose of this study was to analyze local control (LC), liver progression-free survival (PFS), and distant PFS (DFS), overall survival (OS), and toxicity in a cohort of patients treated with stereotactic body radiotherapy (SBRT) with fiducial tracking for oligorecurrent liver lesions; and to evaluate the potential influence of lesion size, systemic treatment, physical and biologically effective dose (BED), treatment calculation algorithms and other parameters on the obtained results...
March 21, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28412138/early-postoperative-fdg-pet-ct-imaging-results-in-a-relevant-upstaging-in-the-pn2-subgroup-of-stage-iii-colorectal-cancer-patients
#20
Martin Fehr, Joachim Müller, Meinhard Knitel, Jürgen Fornaro, Daniel Horber, Dieter Koeberle, Thomas Cerny, Ulrich Güller
INTRODUCTION: Clinical practice guidelines regarding follow-up in patients after curative resection of colorectal cancer (CRC) vary widely. Current follow-up recommendations do not include additional postoperative imaging before starting adjuvant treatment in any patients. We evaluated the potential benefit of our institutional approach, recommending (18)fluor-deoxy-glucose (FDG)-positron emission tomography (PET)-computed tomography (CT) imaging in CRC stage III patients with ≥4 locoregional lymph node metastases (pN2)...
March 21, 2017: Clinical Colorectal Cancer
journal
journal
39741
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"